Xtant Medical Holdings, Inc.

AMEX:XTNT

Medical - Devices

Healthcare
$0.36 -0.16%

-$0.00 today

Market cap
$50.37M
Beta
-0.17
P/E (TTM)
33.4
EPS (TTM)
$0.01
52W Low $0.40High $0.95

Volume 0.16M

Average 0.16M

XTNT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Xtant Medical Holdings, Inc.AMEX: XTNT

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $8.91M fell 29.6% year over year, behind the -10.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 39.0% from the prior quarter. Over 3 fiscal years it compounded at +24.3% a year.

Context

  • Cost of revenue amounted to 37.1% of revenue in FY2025, down 4.8 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -29.6% toward the trailing-twelve-month pace of -10.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.91M-39.0% QoQ
Last fiscal yearDec 2025
$49.65M+1.2% YoY
LTMMar 2026
$45.91M-10.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.6%——
1 year+1.2%——
3-year CAGR+24.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
49.65M USD
Year-over-year change
+1.2%
4-year CAGR
+21.5%

Cost of Revenue vs competitors

How XTNT compares with its peers on the latest reported figures

  • XTNT's LTM Mar 2026 cost of revenue of $45.91M is the 2nd highest of the 8 companies compared; the peer median is $13.48M.
  • Its year-over-year change of -10.2% is the 7th highest of 8, against a peer median of +8.2%.
  • Cost of revenue amounts to 37.7% of revenue for XTNT, versus a peer median of 67.7%.
XTNT Competitors Peer median
Cost of Revenue for XTNT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FONRFONAR CorporationLTM Mar 2026$62.93M +3.9%+6.7%59.7%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$45.91M -10.2%+24.3%37.7%
APYXApyx Medical CorporationLTM Mar 2026$37.86M +65.4%+30.0%67.7%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$30.12M +8.2%+0.4%87.6%
RCELAVITA Medical, Inc.LTM Mar 2026$13.48M +29.5%+28.4%18.6%
LUCDLucid Diagnostics Inc.LTM Mar 2026$7.19M +2.8%+27.8%140.0%
VANIVivani Medical, Inc.LTM Mar 2026$130K +46.1%——
EXOZeXoZymes, Inc.LTM Mar 2026$3.64K -98.7%——
Peer median (excluding XTNT) $13.48M+8.2%+27.8%67.7%

Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.26M57.97M91.3M117.27M133.93M
Cost of Revenue22.77M25.83M35.84M49.05M49.65M
Gross Profit32.49M32.14M55.47M68.22M84.27M
Gross Margin58.8%55.4%60.8%58.2%62.9%
Research & Development870K915K1.34M2.39M2.1M
Selling, General & Admin35.47M37.98M64.29M77.91M74.89M
Operating Expenses36.34M38.89M65.63M80.29M76.99M
Depreciation & Amortization1.34M1.3M3.17M4.22M5.22M
EBITDA(2.51M)(5.43M)5.08M(7.88M)15.9M
EBITDA Margin-4.5%-9.4%5.6%-6.7%11.9%
Operating Income(3.85M)(6.76M)(10.16M)(12.07M)7.28M
Operating Margin-7.0%-11.7%-11.1%-10.3%5.4%
Interest Income031K149K094K
Interest Expense995K1.69M2.94M4.16M3.67M
Other Income / Expenses(995K)(1.66M)9.12M(4.19M)(283K)
Income Before Tax(4.85M)(8.42M)(1.04M)(16.26M)7M
Pre-Tax Margin-8.8%-14.5%-1.1%-13.9%5.2%
Income Tax Expense069K(1.7M)187K2.03M
Net Income(4.85M)(8.49M)660K(16.45M)4.97M
Net Margin-8.8%-14.6%0.7%-14.0%3.7%
EPS (Basic)(0.06)(0.09)0.01(0.12)0.04
EPS (Diluted)(0.06)(0.09)0.01(0.12)0.03
Weighted Avg Shares85.46M94.09M119.09M133.67M139.53M
Weighted Avg Shares (Diluted)85.46M94.09M126.79M133.67M150.04M

Xtant Medical Holdings, Inc.

AMEX:XTNT

Intrinsic Alpha fair value

Locked

Current Price

$0.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.